Daiichi Sankyo Co Ltd
D4S
Company Profile
Business description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
Contact
3-5-1, Nihonbashi-Honcho
Chuo-ku
Tokyo103-8426
JPNT: +81 362251111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
19,765
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.30 | 71.80 | 0.79% |
| CAC 40 | 8,384.01 | 33.14 | 0.40% |
| DAX 40 | 24,894.01 | 258.71 | 1.05% |
| Dow JONES (US) | 51,671.03 | 468.77 | 0.92% |
| FTSE 100 | 10,430.56 | 0.06 | -0.00% |
| HKSE | 24,413.79 | 428.88 | -1.73% |
| NASDAQ | 26,683.94 | 795.10 | 3.07% |
| Nikkei 225 | 69,404.50 | 87.00 | 0.13% |
| NZX 50 Index | 13,426.13 | 65.54 | 0.49% |
| S&P 500 | 7,554.29 | 122.83 | 1.65% |
| S&P/ASX 200 | 8,917.70 | 77.30 | 0.87% |
| SSE Composite Index | 4,092.66 | 3.81 | -0.09% |